Toxicol Appl Pharmacol 2014;281:58-66
In 2014, a meta-analysis of 83 randomized clinical trials were performed showing that DPP-4 inhibition reduced HbA1c by 0.40.5% (45 mmol/mol) when added to metformin [Figure 8, ( Figure 8 Placebo-Controlled Studies With DPP-4 Inhibition as Add-on to Ongoing Sulfonylurea Therapy The DPP-4 inhibitors were as well-examined when added to on-going sulfonylurea in subjects with type 2 diabetes in 2426 week placebo-controlled studies with a total number of 3,282 subjects [Table 2
For More Information The updated 2026 QCP Manual is expected to be released at the end of the year and will include all appropriate information
Management strategies include slower dose titration and temporary dose reduction if needed
Editorial Independence: GLP-1.Reviews maintains full editorial independence
As such, discontinuing therapy solely based on normalized HbA1c may deprive patients, especially those with underlying cardiovascular or renal risk, of organ-protective effects that are both substantial and sustained
